Next GEN Act of 2026
- Sponsor
- Rep. Morelle, Joseph D. [D-NY-25]
- Committees
- Ways and Means Committee (primary)
- Last action
- May 15, 2026
Bottom line
This bill extends market exclusivity for a specific class of novel drugs, potentially impacting drug development incentives and Medicare drug costs.
What it actually does
This bill amends the Social Security Act to extend the period before certain "engineered cyclic peptides" become eligible for the Drug Price Negotiation Program from 7 years to 11 years. It also provides a specific definition for what constitutes an "engineered cyclic peptide" based on its chemical structure, size, development method, origin, and administration route. This change aims to provide drug manufacturers with a longer period of market exclusivity for these specific types of drugs before their prices can be negotiated by Medicare.
Proponents argue
Supporters argue that engineered cyclic peptides represent a cutting-edge area of pharmaceutical innovation, requiring significant research and development investment. Extending the period before price negotiation from 7 to 11 years provides drug manufacturers with a longer period of market exclusivity, which proponents contend is crucial to incentivize investment in these complex and potentially life-saving therapies, ensuring their continued development and availability for patients.
Opponents contend
Opponents would likely argue that extending market exclusivity for any drug class delays the benefits of price negotiation for Medicare beneficiaries and the federal budget. They might contend that even 7 years is sufficient to recoup R&D costs and generate profits, and that an 11-year period would unnecessarily inflate drug prices for longer, placing a greater burden on patients and taxpayers without a clear, proportional benefit to innovation.
The bill is very short and can be read quickly, but understanding its implications requires familiarity with the existing Drug Price Negotiation Program.
Section 2(a)(1) and (2)
Extension of Drug Price Negotiation Exemption for Engineered Cyclic Peptides
This provision modifies the Social Security Act to increase the period during which certain "engineered cyclic peptides" are exempt from the Drug Price Negotiation Program. Currently, qualifying single-source drugs are generally exempt for 7 years. This bill extends that exemption to 11 years specifically for drugs meeting the new definition of an "engineered cyclic peptide," which includes criteria related to their amino acid composition, cyclic structure, size (not more than 40 amino acids), development method (genetically encoded library screening), non-natural origin, and administration route (oral, inhaled, or self-administered).
Supporters argue
Supporters argue that this extension is vital to foster innovation in the complex and high-risk field of engineered cyclic peptides. They contend that the longer exclusivity period provides a stronger financial incentive for companies to invest the substantial capital and time required for R&D, clinical trials, and regulatory approval for these novel therapies, ultimately bringing more new medicines to patients.
Critics contend
Critics would argue that extending exclusivity for an additional four years primarily benefits pharmaceutical companies by allowing them to charge higher prices for longer, increasing costs for Medicare and its beneficiaries. They might contend that the existing 7-year period is already sufficient to incentivize innovation and that this extension would exacerbate drug affordability issues without a guaranteed increase in truly novel drug development.
Tradeoffs
The bill navigates the tension between incentivizing pharmaceutical innovation through market exclusivity and controlling drug costs for patients and the federal government. It aims to strike a balance by offering extended protection for a specific, technically defined class of drugs, hoping to spur development while potentially increasing short-to-medium term drug expenditures.
Defines "engineered cyclic peptide" with six specific criteria, including chemical structure, size, development method, origin, and administration route.
Section 2(a)(2), adding paragraph (5) to Section 1192(e) of the Social Security Act.
Why it matters:This level of detail is standard legislative practice for technical definitions, ensuring precise application of the law. It is not necessarily evasive, but it requires specialized knowledge to fully appreciate its scope and implications.
Case for: Proponents would argue that a precise definition is essential to ensure the extended exclusivity only applies to the intended class of innovative drugs, preventing broader application that could undermine cost-saving measures for other drug types.
Case against: Critics might argue that the highly specific definition could be influenced by particular industry interests, potentially tailoring the criteria to benefit a narrow set of existing or pipeline drugs rather than broadly fostering innovation in a general class.
Estimated impact: The impact is entirely dependent on how many current or future drugs fit this exact definition and their market value. It could be significant if several high-cost drugs qualify.